|ATC code||J07 J07 J07|
| (what is this?)
There are two effective types:
- Ty21a, which is a live vaccine given orally
- Vi capsular polysaccharide vaccine, which is an injectable subunit vaccine
Ty21a is licensed for use from age six years and older. Boosters are recommended annually. The Vi capsular polysaccharide vaccine is licensed for use from age two years and older, and boosters are required every three years.
An experimental vaccine called Vi-rEPA has showed promising results in trials so far, indicating higher effectiveness and longer immunity. However, it has yet to be licensed for use.
Available preparations 
- Vi polysaccharide vaccine: Typhim Vi® (Sanofi Pasteur); Typherix® (GSK)
- Combined hepatitis A/Vi polysaccharide vaccine: ViATIM® (Sanofi Pasteur); Hepatyrix® (GSK)
- Ty21a oral vaccine: Vivotif® (Crucell)
- Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L (2007). "Vaccines for preventing typhoid fever". Cochrane Database Syst Rev (3): CD001261. doi:10.1002/14651858.CD001261.pub2. PMID 17636661.
- Salisbury, D; Ramsay, M; Noakes, K. ""Chapter 33: Typhoid"". Immunisation against infectious disease. Department of Health. p. 418. ISBN 0-11-322528-8.
|This vaccine article is a stub. You can help Wikipedia by expanding it.|